Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jan
21
2015
Teva v. Sandoz pt.II– The Dissent And The Zone Of Uncertainty Schwegman, Lundberg & Woessner, P.A.
Mar
19
2015
Enzo Biochem V. Applera Corp. – When “Words Can Hurt You” Schwegman, Lundberg & Woessner, P.A.
Mar
22
2016
Sequenom Files Petition for Cert. After Invalidation of Cff Patent Schwegman, Lundberg & Woessner, P.A.
Mar
16
2020
INO v. Praxair – Time for the Supreme Court to Step Up to the Plate? Schwegman, Lundberg & Woessner, P.A.
Mar
17
2020
Illumina v. Ariosa – The “Bucket” to be in Schwegman, Lundberg & Woessner, P.A.
Sep
24
2012
Appellate Court Ruling Permits Continued NIH Funding of Embryonic Stem Cell Research Schwegman, Lundberg & Woessner, P.A.
Oct
11
2012
Federal Circuit to Address Computer-Implemented Inventions En Banc Schwegman, Lundberg & Woessner, P.A.
Feb
17
2013
Biotech’s Public Relations Problems Continue Schwegman, Lundberg & Woessner, P.A.
Apr
23
2013
Marks & Clerk Releases Life Sciences 2013 Report Schwegman, Lundberg & Woessner, P.A.
May
14
2013
En (many) Banc(s) Federal Circuit Decides CLS Bank v. Alice Corp. Schwegman, Lundberg & Woessner, P.A.
Jul
12
2018
Is Judge Kavenaugh an Enemy of Agency “Chevron Deference”? Schwegman, Lundberg & Woessner, P.A.
Aug
4
2014
Ignorance is Bliss – for Teva re: Structural Obviousness in Patent Cases Schwegman, Lundberg & Woessner, P.A.
Jun
13
2019
Senate Subcommittee Hearing of Patent Eligibility Wrap Up – Now What? Schwegman, Lundberg & Woessner, P.A.
Apr
16
2015
Genetic Engineering Makes the Blacklist Schwegman, Lundberg & Woessner, P.A.
Jun
12
2015
Ariosa v. Sequenom – Novel Genetic Analysis Fails The Mayo Test Schwegman, Lundberg & Woessner, P.A.
Nov
21
2022
China’s Supreme People’s Court Releases Draft Judicial Interpretation of Anti-Monopoly Civil Procedures for Comment Schwegman, Lundberg & Woessner, P.A.
Oct
11
2019
OSI v. Apotex – Christmas in October! Schwegman, Lundberg & Woessner, P.A.
Sep
26
2016
Vanda v. Roxane Labs. – Are Two Natural Laws Better Than One? Schwegman, Lundberg & Woessner, P.A.
Sep
26
2012
Akami/McKesson Decision Re-defines Induced Infringement Schwegman, Lundberg & Woessner, P.A.
Jan
26
2018
Chinese Team Reports Cloning Two Monkeys Using the Same Nuclear Donor – But Don’t Try to Patent Them! Schwegman, Lundberg & Woessner, P.A.
Feb
22
2013
Supreme Court Hears “Replicant Soy Bean” Appeal Schwegman, Lundberg & Woessner, P.A.
Jun
13
2013
Supreme Court Rules In Myriad On Patentability Of DNA Schwegman, Lundberg & Woessner, P.A.
Sep
3
2013
Dr. Watson, Genomics and the Law Schwegman, Lundberg & Woessner, P.A.
Dec
2
2013
The Unacknowledged Role of Section 112 in the Myriad Decisions Re: Patent Eligibility of Genomic DNA Schwegman, Lundberg & Woessner, P.A.
Sep
11
2014
Indefiniteness After The Supreme Court Nautilus Decision – A Very “Delicate Balance” Schwegman, Lundberg & Woessner, P.A.
May
22
2023
Supreme Court Voids Amgen’s Patents using “Undue Experimentation” Standard Schwegman, Lundberg & Woessner, P.A.
Jun
3
2020
Chinese Patent Application for Coronavirus Vaccine Published Schwegman, Lundberg & Woessner, P.A.
Dec
23
2023
China’s National Intellectual Property Administration to Allow Third-Party Challenges to Pharmaceutical Patent Term Extensions Schwegman, Lundberg & Woessner, P.A.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins